Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE
Monte Rosa Therapeutics — AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10 slides from Monte Rosa Therapeutics's conference presentation
Slide 1: Identification of GSPT1-mediated molecular glue degraders for the treatment of Myc-driven cancers
Identification of GSPT1-mediated molecular glue degraders for the treatment of Myc-driven cancers LBA004 Dr Gerald Gavory Monte Rosa Therapeutics Inc.
Slide 2: Financial relationships disclosure
Gerald Gavory I have the following financial relationships to disclose: Employee of: Monte Rosa Therapeutics I will not discuss off label use and/or investigational use in my presentation.
Slide 3: Molecular Glue Degraders (MGDs)
Molecular Glue Degraders (MGDs) Opportunities for expanding the target space and fostering a new generation of drugs DO NOT POST
Slide 4: Targeting Myc-driven Tumors and Their Addiction to Protein Translation
Targeting Myc-driven Tumors and Their Addiction to Protein Translation GSPT1 is a key regulator and vulnerability of Myc-induced translational addiction DO NOT POST
Slide 5: MRT-048 a Potent, Selective GSPT1 Degrader for Myc-driven Cancers
MRT-048 a Potent, Selective GSPT1 Degrader for Myc-driven Cancers Replicating and targeting Myc biology in a breast model system DO NOT POST
Slide 6: MRT-048 Sensitivity is Linked to Key Regulators of Protein Translation including p4EBP1
MRT-048 Sensitivity is Linked to Key Regulators of Protein Translation including p4EBP1 in Breast Cancer Cell Lines DO NOT POST
Slide 7: MRT-048 in vivo Efficacy Studies in High p4EBP1 Breast Cancer Models
MRT-048 in vivo Efficacy Studies in High p4EBP1 Breast Cancer Models Potent anti-tumor activity and target engagement demonstrated DO NOT POST
Slide 8: MRT-048 Impairs Protein Translation and Myc Oncogenic Signaling
MRT-048 Impairs Protein Translation and Myc Oncogenic Signaling Myc gene signatures are strongly down-regulated following treatment with MRT-048 DO NOT POST
Slide 9: Targeting Myc-addicted Tumors with GSPT1 MGDs
Targeting Myc-addicted Tumors with GSPT1 MGDs DO NOT POST
Slide 10: Acknowledgements
wom GyEORTC Ae ee Nile) CANCER ‘ofrecer for Cancer Research STAG ie eatecten cat aery FINDING CURES TOGETHER” Acknowledgements MM verterers, ICR S Ridgeline Gerald Gavory Hannah Wang Frederic Delobel Bernhard Fasching llona Bernett Alexander Flohr Markus Warmuth Laura Chan Giorgio Ottaviani Silvia B